VJHemOnc is committed to improving our service to you

Single use daratumumab for AL amyloidosis

VJHemOnc is committed to improving our service to you

Daratumumab is a monoclonal antibody that binds to CD38, resulting in immune-mediated tumor cell death via apoptosis. Oliver Charles Cohen, MD, University College London Hospitals NHS Foundation Trust, London, UK, discusses rapid responses to single-agent daratumumab and the therapeutics association with improved progression-free survival in relapsed/refractory AL amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).


Warning: count(): Parameter must be an array or an object that implements Countable in /home/vjhemonc/public_html/wp-content/themes/vj/single.php on line 248
Share this video  
14th September 2020

Warning: Invalid argument supplied for foreach() in /home/vjhemonc/public_html/wp-content/themes/vj/single.php on line 443

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter